 |
 Video: What is a Stock Split?
|
|
|
| Inventiva is a clinical-stage biopharmaceutical company. Co. is developing its product candidate, lanifibranor, for the treatment of patients with non-alcoholic steatohepatitis (NASH). Lanifibranor is an orally-available small molecule in development for the treatment of NASH that acts to induce anti-fibrotic, anti-inflammatory and beneficial vascular and metabolic changes in the body by activating all three peroxisome proliferator-activated receptor isoforms. Co.'s other product candidate is odiparcil, which it developed for the treatment of patients with mucopolysaccharidoses. Odiparcil is an orally-available small molecule designed to modify how glycosaminoglycans are synthesized. According to our Inventiva SA stock split history records, Inventiva SA has had 0 splits. | |
|
Inventiva SA (IVA) has 0 splits in our Inventiva SA stock split history database.
Looking at the Inventiva SA stock split history from start to finish, an original position size of 1000 shares would have turned into 1000 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into Inventiva SA shares, starting with a $10,000 purchase of IVA, presented on a split-history-adjusted basis factoring in the complete Inventiva SA stock split history.
Growth of $10,000.00
Without Dividends Reinvested
|
| Start date: |
07/13/2020 |
|
| End date: |
04/26/2024 |
|
| Start price/share: |
$10.85 |
|
| End price/share: |
$3.25 |
|
| Dividends collected/share: |
$0.00 |
|
| Total return: |
-70.05% |
|
| Average Annual Total Return: |
-27.25% |
|
| Starting investment: |
$10,000.00 |
|
| Ending investment: |
$2,995.57 |
|
| Years: |
3.79 |
|
|
|
|
|
